Document:EU EMA Guidelines -: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Migrate to Template:DocumentData for PageForms (GxPlexBot) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
|reference=EU EMA Guidelines - | |reference=EU EMA Guidelines - | ||
|validity_area=EU | |validity_area=EU | ||
Latest revision as of 12:54, 16 July 2026
| Document information | |
|---|---|
| Reference | EU EMA Guidelines - |
| Validity area | EU |
| Scope(s) | HM |
| Document name | EMA Guidelines |
| Version / Revision | - |
| Status | N.A. |
| Document type | Corpus of texts |
| Language(s) | EN |
| Description | European Medicines Agency (EMA)
Examples: - EMA/INS/GCP/112288/2023 - Guideline on computerised systems and electronic data in clinical trials - EMA/INS/GCP/126568/2023 – Annual Report of the Good Clinical Practice [GCP) Inspectors' Working Group [IWG) 2022 - EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation [EU) No 536/2014 or the clinical trial protocol |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
No references yet.
